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A commentary on
L-3-n-butylphthalide Rescues Hippocampal Synaptic Failure and Attenuates Neuropathology
in Aged APP/PS1 Mouse Model of Alzheimer’s Disease
by Zhang, Y., Huang, L. -J., Shi, S., Xu, S. -F., Wang, X. -L., and Peng, Y. (2016). CNS Neurosci. Ther.
22, 979–987. doi: 10.1111/cns.12594
According to World Health Organization estimation about 18 million people worldwide are
suffering from Alzheimer’s disease (AD) and figures would shoot up to 34 million by 2025 in
aging population. The onset and propagation of AD is unrelenting from cellular to molecular levels,
governed by multitude of factors leading to a continual decrease in cognitive abilities (Felsenstein
et al., 2014). Recent advances in understanding the genetic factors that predispose to AD, as well
as in biomarker development have brought with them the promise of earlier and more reliable
diagnosis of this disease. However, treatment regime and strategies available, approved by US-FDA
are limited by their scope to alter pharmacological targets that can provide symptomatic relief to the
patient (Lannfelt et al., 2014). The present stock of drugs for AD consists of donepezil, galantamine,
rivastigmine, and memantine. The primary mechanism of action for these drugs is to decrease
the acetyl cholinesterase (AChE) levels thus altering acetylcholine level, while memantine is a
low-affinity voltage-dependent uncompetitive antagonist at glutamatergic N-methyl d-aspartate
receptor (NMDA) thereby blocking the activity of the neurotransmitter glutamate. All the existing
treatments for AD are only symptomatic but non curative (Lannfelt et al., 2014). Under these
circumstances a drug molecule with multiple pharmacological properties with intent to modify
as well as reduce the risk factors contributing toward disease burden will be highly appreciated.
Drugs that are aimed at disrupting AD disease progression by inhibition/degradation of the protein
mis-folding of β-amyloid (Aβ) into neurotoxic oligomeric aggregates has been encouraged for AD
(Scheff et al., 2007).
With the advent of new diagnostic tools various pathological conditions have been identified at
different stages of AD. Accumulation of amyloid beta (Aβ) to form clumps known as neuritic or
senile plaques is considered as hallmark of AD. The buildup of these plaques seems to be a crucial as
they lead to oxidative stress coupled with mitochondrial dysfunction and barrage of inflammatory
cascade causing neuronal cell death. Studies carried by Zhang et al. (2016) on L-3-n-butylphthalide
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FIGURE 1 | L-NBP promotes synaptic number and synaptic strength by modulating several key proteins.
(L-NBP) extracted from seeds of Chinese celery (Apium
graveolens Linn) showed some promising results in animal
models of AD. Interestingly treatment of L-NBP (15 mg/kg;
oral, 3 months) to APP/PS1 mice resulted in amelioration
of Aβ induced damage to synapse. Improvement in synaptic
plasticity which is considered as an essential factor modulating
cognitive functions in AD has also been observed after L-
NBP. Pictorial results from electron microscopy revealed the
significant increase in number of synapse and spines in
hippocampus regions following treatment with L-NBP. It could
be reasoned that multiple molecular events have been amended
to bring about changes in synaptic strength. These changes
might range from removal of synaptic plaques to anti oxidative
and anti-inflammatory mechanisms. However, it is very hard to
distinguish whether removal of synaptic plaques provides anti
oxidative and anti-inflammatory relief or vice versa. In this study
Zhang et al. (2016) explored pertinent proteins associated with
synaptic plasticity in hippocampus to unveil the mechanism
of neuroprotective effects of L-NBP and found upregulation
in expression of PSD95, synaptophysin, β-catenin and GSK-
3β on treatment with L-NBP. PDS-95 is an abundant synaptic
protein playing an important role in maintaining and regulating
excitatory synapses and promoting synaptogenesis. β-catenin is
a crucial factor for Wnt signaling pathway necessary for the
maintenance of dendritic strength and density. An important
issue remaining unanswered in these studies was involvement
of adult neurogenesis following exposure to L-NBP. Since it
affects multiple pharmacological targets it could be reasoned
that L-NBP might alter stem cells in the hippocampal region
to bring about changes in synaptic plasticity by involving the
Wnt pathway. Whether the potential of L-NBP is limited to the
degradation of Aβ or it might regulate proteins associated with
adult neurogenesis via activation of stem cell markers in AD still
remains elusive (Lei et al., 2014).
Interestingly, L-NBP influence on inflammatory responses
during AD has been previously reported involving decreased
expression of IBA-1 and inhibition of microglia activation
in APP/PS1 mice. Furthermore, significant decrease in Aβ
deposition linked with decreased gliosis has also been observed
on after L-NBP exposure highlighting potential effects of the
compound in ameliorating inflammation. Anti-inflammatory
potential of L-NBP is well documented wherein it reduced neuro
inflammation in lipopolysaccharide-treated C57BL/6 mice. The
anti-inflammatory response could be beneficial in long term
therapy in case of neurodegenerative disorders (Lei et al., 2014;
Zhang et al., 2016).
Mitochondria are considered a target in neurodegenerative
disorder since reactive oxygen species generated during ATP
generation tip the balance toward neuronal damage and
apoptosis (Figure 1). Elevated levels of mitochondrial ROS
particularly in the neurons may target the lipid bilayers and cause
neurochemical alterations. Further, compromised membrane
potential could be associated with enhanced apoptosis due
to activation of intrinsic apoptotic pathway. Amelioration of
oxidative damage either through chelating ROS or promoting
the expression of anti-oxidant enzymes is considered a potential
mechanism through which L-NBP exerts its anti-oxidant effect
(Peng et al., 2008, 2010).
Taken together, the findings suggest that the neurotherapeutic
potential of L-NBP as a disease modifier in AD is due to its
multiple pharmacological properties. It may be hypothesized
from the experimental findings that the specific feature of this
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compound is the ability to reduce the load of Aβ and to
exert anti-oxidant properties by lowering the levels of ROS,
maintaining optimum MMP with reduction in inflammatory
markers. For the first time Zhang et al. (2016) have demonstrated
that this molecule could also repair synaptic damages via
modulation of PSD95, synaptophysin (SYN), β-catenin, and
GSK-3 β. L-NBP acts through various systems to impede
progression of AD. Previous studies with L-NBP in patient
with subcortical vascular cognitive impairment without dementia
have demonstrated improved cognitive and global functioning
and good safety (Jia et al., 2016). Another study by Xiang
et al. (2014) also supported the neuroprotective role of L-BNP
in an AD model by inhibiting oxidative injury, neuronal
apoptosis and glial activation, regulating amyloid-beta protein
precursor processing and reducing amyloid-beta formation.
These studies substantiate the necessity of further evaluations of
L-NBP for its potential beneficial effects in neurological diseases.
However, the clinical efficacy of the molecule still requires to
be evaluated. Bioavailability is considered as another major
issue faced by natural compounds during clinical trials. Until
disease-modifying therapies become available, further research
is needed to develop new drug delivery strategies to ensure
ease of administration and adequate pharmacokinetic properties,
since no available treatments stop or reverse the progression
of the disease. As of 2016, more than 1000 clinical trials
have been or are being conducted to find ways to treat the
disease, but it is unknown if any of the tested treatments will
work.
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